Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab

Nivolumab, a monoclonal antibody to programmed cell death protein-1 (PD-1), has revolutionised the management of patients with advanced non-small cell lung cancer (NSCLC). Treatment with nivolumab is associated with toxicities known as immune-related adverse events. Although pneumonitis is a potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Ryoji, Hayashi, Hidetoshi, Tanizaki, Junko, Tanaka, Kaoru, Takeda, Masayuki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ESMO Open 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519799/
https://www.ncbi.nlm.nih.gov/pubmed/28761729
http://dx.doi.org/10.1136/esmoopen-2016-000145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519799/
https://www.ncbi.nlm.nih.gov/pubmed/28761729
http://dx.doi.org/10.1136/esmoopen-2016-000145

Ejemplares similares